Method and kit for evaluating risk of ovarian cancer in carriers of a BRCA1 mutation

摘要

The association between the presence of one or more rare (infrequent) alleles of the HRAS variable tandem repeat (VTR) polymorphism and the incidence of ovarian cancer in women who harbor a BRCA1 mutation can be used for evaluating risk of ovarian cancer in a human patient. The patient is tested for the presence of a mutation in the BRCA1 gene; and to determine the polymorphic form of the HRAS1 variable tandem repeat region. The presence of both a mutation in the BRCA1 gene and a rare polymorphic form of the HRAS1 variable tandem repeat region is indicative of an elevated risk of developing ovarian cancer. A kit for performing this evaluation includes reagents necessary for performing a test for the BRCA1 mutation and to evaluate the polymorphic form of the HRAS1 variable tandem repeat region.